vs
Side-by-side financial comparison of MARRIOTT VACATIONS WORLDWIDE Corp (VAC) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 1.9× MARRIOTT VACATIONS WORLDWIDE Corp). Zoetis runs the higher net margin — 25.3% vs -35.0%, a 60.3% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -0.7%). Zoetis produced more free cash flow last quarter ($732.0M vs $-6.0M). Over the past eight quarters, MARRIOTT VACATIONS WORLDWIDE Corp's revenue compounded faster (5.2% CAGR vs 4.4%).
Marriott Vacations Worldwide Corporation is a pure-play public timeshare company. Formerly a division of Marriott International, Marriott Vacations Worldwide was established as a separate, publicly traded entity focusing primarily on vacation ownership in November 2011. Marriott Vacations Worldwide runs more than 120 resorts with over 700,000 Owners and members in a diverse portfolio of brands under The Marriott Vacation Clubs name. Its brands include Marriott Vacation Club, The Marriott Vaca...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
VAC vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $-431.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | -35.0% | 25.3% |
| Revenue YoY | -0.7% | 3.0% |
| Net Profit YoY | -962.0% | 3.8% |
| EPS (diluted) | $-12.00 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.2B | $2.4B | ||
| Q2 24 | $1.1B | $2.4B | ||
| Q1 24 | $1.1B | $2.2B |
| Q4 25 | $-431.0M | $603.0M | ||
| Q3 25 | $-2.0M | $721.0M | ||
| Q2 25 | $69.0M | $718.0M | ||
| Q1 25 | $56.0M | $631.0M | ||
| Q4 24 | $50.0M | $581.0M | ||
| Q3 24 | $84.0M | $682.0M | ||
| Q2 24 | $37.0M | $624.0M | ||
| Q1 24 | $47.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | — | 34.1% |
| Q4 25 | -35.0% | 25.3% | ||
| Q3 25 | -0.2% | 30.0% | ||
| Q2 25 | 6.0% | 29.2% | ||
| Q1 25 | 5.0% | 28.4% | ||
| Q4 24 | 4.0% | 25.1% | ||
| Q3 24 | 6.9% | 28.6% | ||
| Q2 24 | 3.5% | 26.4% | ||
| Q1 24 | 4.2% | 27.4% |
| Q4 25 | $-12.00 | $1.37 | ||
| Q3 25 | $-0.07 | $1.63 | ||
| Q2 25 | $1.77 | $1.61 | ||
| Q1 25 | $1.46 | $1.41 | ||
| Q4 24 | $1.29 | $1.29 | ||
| Q3 24 | $2.12 | $1.50 | ||
| Q2 24 | $0.98 | $1.37 | ||
| Q1 24 | $1.22 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $406.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.0B | $3.3B |
| Total Assets | $9.8B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $406.0M | — | ||
| Q3 25 | $474.0M | $2.1B | ||
| Q2 25 | $205.0M | $1.4B | ||
| Q1 25 | $196.0M | $1.7B | ||
| Q4 24 | $197.0M | $2.0B | ||
| Q3 24 | $197.0M | $1.7B | ||
| Q2 24 | $206.0M | $1.6B | ||
| Q1 24 | $237.0M | $2.0B |
| Q4 25 | $2.0B | $3.3B | ||
| Q3 25 | $2.5B | $5.4B | ||
| Q2 25 | $2.5B | $5.0B | ||
| Q1 25 | $2.4B | $4.7B | ||
| Q4 24 | $2.4B | $4.8B | ||
| Q3 24 | $2.4B | $5.2B | ||
| Q2 24 | $2.4B | $5.0B | ||
| Q1 24 | $2.4B | $5.1B |
| Q4 25 | $9.8B | $15.5B | ||
| Q3 25 | $10.1B | $15.2B | ||
| Q2 25 | $9.9B | $14.5B | ||
| Q1 25 | $9.9B | $14.1B | ||
| Q4 24 | $9.8B | $14.2B | ||
| Q3 24 | $9.7B | $14.4B | ||
| Q2 24 | $9.6B | $14.2B | ||
| Q1 24 | $9.9B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.0M | $893.0M |
| Free Cash FlowOCF − Capex | $-6.0M | $732.0M |
| FCF MarginFCF / Revenue | -0.5% | 30.7% |
| Capex IntensityCapex / Revenue | 1.0% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-29.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | $893.0M | ||
| Q3 25 | $62.0M | $938.0M | ||
| Q2 25 | $-48.0M | $486.0M | ||
| Q1 25 | $8.0M | $587.0M | ||
| Q4 24 | $100.0M | $905.0M | ||
| Q3 24 | $72.0M | $951.0M | ||
| Q2 24 | $30.0M | $502.0M | ||
| Q1 24 | $3.0M | $595.0M |
| Q4 25 | $-6.0M | $732.0M | ||
| Q3 25 | $51.0M | $805.0M | ||
| Q2 25 | $-68.0M | $308.0M | ||
| Q1 25 | $-6.0M | $438.0M | ||
| Q4 24 | $86.0M | $689.0M | ||
| Q3 24 | $58.0M | $784.0M | ||
| Q2 24 | $17.0M | $370.0M | ||
| Q1 24 | $-13.0M | $455.0M |
| Q4 25 | -0.5% | 30.7% | ||
| Q3 25 | 4.3% | 33.5% | ||
| Q2 25 | -5.9% | 12.5% | ||
| Q1 25 | -0.5% | 19.7% | ||
| Q4 24 | 6.9% | 29.7% | ||
| Q3 24 | 4.8% | 32.8% | ||
| Q2 24 | 1.6% | 15.7% | ||
| Q1 24 | -1.2% | 20.8% |
| Q4 25 | 1.0% | 6.7% | ||
| Q3 25 | 0.9% | 5.5% | ||
| Q2 25 | 1.7% | 7.2% | ||
| Q1 25 | 1.3% | 6.7% | ||
| Q4 24 | 1.1% | 9.3% | ||
| Q3 24 | 1.1% | 7.0% | ||
| Q2 24 | 1.2% | 5.6% | ||
| Q1 24 | 1.4% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | -0.70× | 0.68× | ||
| Q1 25 | 0.14× | 0.93× | ||
| Q4 24 | 2.00× | 1.56× | ||
| Q3 24 | 0.86× | 1.39× | ||
| Q2 24 | 0.81× | 0.80× | ||
| Q1 24 | 0.06× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VAC
| Cost Reimbursement | $467.0M | 38% |
| Time Share | $381.0M | 31% |
| Management And Exchange | $212.0M | 17% |
| Ancillary Revenues | $64.0M | 5% |
| Management Service | $55.0M | 4% |
| Service Other | $36.0M | 3% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
